110 results about "IMMUNE SUPPRESSANTS" patented technology

Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments.

The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein Y, L, X1, X2, Z, R3, R4, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.

Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft / tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and / or suppression of IL-2 secretion

Disclosed are synthetic nanocarrier methods, and related compositions, comprising B cell and / or MHC Class II-restricted epitopes and immunosuppressants in order to generate tolerogenic immune responses, such as the generation of antigen-specific regulatory B cells.

A pharmaceutical ointment composition is provided comprising (a) a therapeutically effective amount of one or more active pharmaceutical ingredients comprising one or more macrolide related immunosuppressants or pharmaceutically acceptable salts or esters thereof; (b) an ointment base; and (c) an effective amount of one or more skin penetration enhancers capable of percutaneous delivery of the macrolide related immunosuppressant through the skin. Also provided is a process for its preparation and methods for delivering a macrolide related immunosuppressant or a pharmaceutically acceptable salt or ester thereof through the skin of a mammal in order to treat conditions situated on and beneath the skin.

A method of enhancing an antigen-specific immune response in a host comprising administering to the host an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, in an amount effective to enhance an antigen-specific immune response; as well as a pharmaceutical composition comprising an HMGN polypeptide comprising at least one of HMGN1, HMGN3a, HMGN3b, HMGN4, Nsbp1, or a functional fragment thereof, and an antigen, or nucleic acids encoding such molecules; and related methods and compositions.

Isolated immunomodulatory (e.g. immunostimulatory) polyhydroxlated pyrrolizidine compounds having the formula are disclosed. In these compounds R is selected from hydrogen, straight or branched, unsubstituted or substituted, saturated or unsaturated acyl, alkyl (e.g. cycloalkyl), alkenyl, alkynyl and aryl groups. The compounds are useful in therapy and prophylaxis, including increasing the Th1:Th2 response ratio, hemorestoration, alleviation of immunosuppression, cytokine stimulation, treatment of proliferative disorders (e.g. cancer), vaccination, stimulation of the innate immune response and boosting of the activity of endogenous NK cells.

The level of miRNAs in a sample from a patient who has received a transplant is assayed and used as an indicator for transplant rejection. Based on the measured level of the miRNAs, therapeutic intervention, such as an immunosuppressant therapy, may be started, adjusted, continued or discontinued.

Provided herein are methods and related compositions or kits for administering viral transfer vectors in combination with synthetic nanocarriers comprising an immunosuppressant and a corticosteroid.

The invention relates to the application of VEGFR fusion proteins FP1, FP3, FP7 and FP8 in the preparation of drugs for treating ocular surface neovascularization and relevant diseases and a combined preparation of fusion proteins FP1, FP3, FP7, FP8 and an immunosuppressant, wherein the immunosuppressant is one or a combination selected from the group consisting of corticosteroid, rapamycin, dexamethasone and cyclosporine A; and amino acid sequences of FP1, FP3, FP7 and FP8 are respectively as shown in SEQ ID NO:1, 2, 3, 4.

It is intended to provide an evaluation method and a screening method capable of eliminating a substance that disturbs in vivo kinetics in an individual and capable of simply and easily searching a substance having an action of activating / suppressing an innate immune mechanism without being affected by LPS derived from bacteria, which can be contaminated during the search, as well as a drug and a food for activating / suppressing the innate immune mechanism, and methods of producing the same. The present invention provides a method of evaluating or screening the substance having the action of activating / suppressing the innate immune mechanism using a muscular contraction of an organism having the innate immune mechanism as an indicator, and methods of producing the drug and the food for activating / suppressing the innate immune mechanism. Also, an innate immunity activator and the food having the action of activating the innate immune mechanism containing the substance having the action of contracting the muscle of the organism having the innate immune mechanism, and an innate immunity suppressor and the food having the action of suppressing the innate immunity containing the substance having the action of suppressing the contraction of the muscle of the organism having the innate immune mechanism are provided.

The present invention relates to a fused imidazole derivative having IDO / TDO inhibition activity and having a structure represented by a formula (I), a preparation method and applications thereof. According to the present invention, the series of the fused imidazole derivatives have high IDO / TDO inhibition activity, can be widely used for treating or preventing cancers or tumors, viral infections, depression, neurodegenerative disorders, trauma, age-related cataract, organ transplant rejections or autoimmune diseases, can further be used to inhibit the immune suppression of patients, and are expected to be developed into the new generation of the immunosuppressive agent. The formula (I) is defined in the specification.

The invention relates to a preparation method of animal model simulating human pelvic inflammatory disease (PID). The method comprises the steps of selecting animal of family Muridae without reproductive tract diseases; and under sterile condition, inoculating strain of genus Enterobacter, genus Staphylococcus or genus Candida in animal vagina for 1-8 weeks and 1-7 times every week. The invention has the advantages of high model preparation success ratio and no dependence on immunity inhibitor. After success of model preparation, vaginal secretion obviously increases; bacteria can be observed by vaginal smear microscopic examination; metryperemia, abscess and ovarian cyst can be observed after dissection. Large amount of inflammatory cell infiltration can be observed in uterus and oviduct by organ tissue section microscopic examination. Blood examination indicates abnormal rise of neutrophil count. The method has the advantages of simple implementation, easily-accessible materials, easy grasping without special technical requirements for operator, accordance with clinical natural occurrence process of PID, and suitability for research of generation, development and mechanism of PID and screening of relevant drugs.